Significant contract signed to manufacture lateral flow device components
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer
Placing of 50,000,000 New Ordinary Shares and Warrants
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AIM:AVCT) Poster presented at the AACR available to download
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Novacyt S.A. (AIM:NCYT) Approval of COVID-19 test under CTDA legislation
Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Avacta Group PLC (AIM:AVCT) AffyXell partners with Biocytogen and KNTSC
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
Omega Diagnostics Gp (AIM:ODX) Trading Update
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
